Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Special Offers and Promotions


Microscopy | Image Analysis



View Channel

Separation Science



View Channel

Coronavirus (COVID-19)



View Channel

Research & Case Studies



View Channel

Conferences | Events

Differential diagnosis of Plasmodium falciparum with bioMérieux’s new VIKIA Malaria Ag Pf/Pan rapid test

publication date: Feb 25, 2014
author/source: bioMérieux

VIKIA® Malaria Ag Pf/Pan

bioMérieux has further extended its range of rapid tests for infectious diseases with the launch of VIKIA Malaria Ag Pf/Pan.

This qualitative immunochromatographic test differentiates between Plasmodium falciparum and other less virulent malarial species, enabling rapid, effective diagnosis and allowing swift initiation of the appropriate treatment.

The VIKIA Malaria Ag Pf/Pan test is an easy-to-use lateral flow assay that enables malarial infections to be detected in whole blood specimens in just 20 minutes, without the need for any additional equipment or specific training. Monoclonal antibodies target the antigens HRP­II, which is specific to P. falciparum (P.f.), and Pan (aldolase), common to all Plasmodium species. Any antigens present in the sample form complexes with specific antibodies coupled to gold particles. These complexes migrate along the membrane to the Pf and/or Pan regions of the test result window by capillary flow, where they are captured by immobilised antibodies. Interpretation of the result is simple; the formation of a red line in one or both test regions indicates a positive test result, with the location of the line(s) differentiating between an infection caused by P. falciparum and other species, or a probable mixed infection. A third (control) band confirms that the test has performed correctly.

Supplied in an economical 25-test pack, VIKIA Malaria Ag Pf/Pan is stable at 2-30 °C for up to 24 months

more about VIKIA® Malaria Ag Pf/Pan 

About bioMérieux

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached €1.357 billion with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

more about bioMérieux

more news from bioMérieux

If you have not logged into the website then please enter your details below.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners